2009 Santa Fe Bone Symposium

E. Michael Lewiecki, John P. Bilezikian, Andrew J. Laster, Paul D. Miller, Robert R. Recker, R. Graham G Russell, Michael P. Whyte

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Osteoporosis is a common skeletal disease with serious clinical consequences because of fractures. Despite the availability of clinical tools to diagnose osteoporosis and assess fracture risk, and drugs proven to reduce fracture risk, it remains a disease that is underdiagnosed and undertreated. When treatment is started, it is commonly not taken correctly or long enough to be effective. Recent advances in understanding of the regulators and mediators of bone remodeling have led to new therapeutic targets and the development of drugs that may offer advantages over current agents in reducing the burden of osteoporotic fractures. Many genetic factors that play a role in the pathogenesis of osteoporosis and metabolic bone disease have now been identified. At the 2009 Santa Fe Bone Symposium, held in Santa Fe, New Mexico, USA, the links between advances in genetics, basic bone science, recent clinical trials, and new and emerging therapeutic agents were presented and explored. Socioeconomic challenges and opportunities in the care of osteoporosis were discussed. This is a collection of medical essays based on key presentations at the 2009 Santa Fe Bone Symposium.

Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalJournal of Clinical Densitometry
Volume13
Issue number1
DOIs
StatePublished - Jan 2010

Fingerprint

Osteoporosis
Bone and Bones
Osteoporotic Fractures
Bone Remodeling
Metabolic Bone Diseases
Reducing Agents
Pharmaceutical Preparations
Clinical Trials
Therapeutics

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging
  • Orthopedics and Sports Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Lewiecki, E. M., Bilezikian, J. P., Laster, A. J., Miller, P. D., Recker, R. R., Russell, R. G. G., & Whyte, M. P. (2010). 2009 Santa Fe Bone Symposium. Journal of Clinical Densitometry, 13(1), 1-9. https://doi.org/10.1016/j.jocd.2009.12.003

2009 Santa Fe Bone Symposium. / Lewiecki, E. Michael; Bilezikian, John P.; Laster, Andrew J.; Miller, Paul D.; Recker, Robert R.; Russell, R. Graham G; Whyte, Michael P.

In: Journal of Clinical Densitometry, Vol. 13, No. 1, 01.2010, p. 1-9.

Research output: Contribution to journalReview article

Lewiecki, EM, Bilezikian, JP, Laster, AJ, Miller, PD, Recker, RR, Russell, RGG & Whyte, MP 2010, '2009 Santa Fe Bone Symposium', Journal of Clinical Densitometry, vol. 13, no. 1, pp. 1-9. https://doi.org/10.1016/j.jocd.2009.12.003
Lewiecki EM, Bilezikian JP, Laster AJ, Miller PD, Recker RR, Russell RGG et al. 2009 Santa Fe Bone Symposium. Journal of Clinical Densitometry. 2010 Jan;13(1):1-9. https://doi.org/10.1016/j.jocd.2009.12.003
Lewiecki, E. Michael ; Bilezikian, John P. ; Laster, Andrew J. ; Miller, Paul D. ; Recker, Robert R. ; Russell, R. Graham G ; Whyte, Michael P. / 2009 Santa Fe Bone Symposium. In: Journal of Clinical Densitometry. 2010 ; Vol. 13, No. 1. pp. 1-9.
@article{d41302ab8e494db3a74d32f7be019af7,
title = "2009 Santa Fe Bone Symposium",
abstract = "Osteoporosis is a common skeletal disease with serious clinical consequences because of fractures. Despite the availability of clinical tools to diagnose osteoporosis and assess fracture risk, and drugs proven to reduce fracture risk, it remains a disease that is underdiagnosed and undertreated. When treatment is started, it is commonly not taken correctly or long enough to be effective. Recent advances in understanding of the regulators and mediators of bone remodeling have led to new therapeutic targets and the development of drugs that may offer advantages over current agents in reducing the burden of osteoporotic fractures. Many genetic factors that play a role in the pathogenesis of osteoporosis and metabolic bone disease have now been identified. At the 2009 Santa Fe Bone Symposium, held in Santa Fe, New Mexico, USA, the links between advances in genetics, basic bone science, recent clinical trials, and new and emerging therapeutic agents were presented and explored. Socioeconomic challenges and opportunities in the care of osteoporosis were discussed. This is a collection of medical essays based on key presentations at the 2009 Santa Fe Bone Symposium.",
author = "Lewiecki, {E. Michael} and Bilezikian, {John P.} and Laster, {Andrew J.} and Miller, {Paul D.} and Recker, {Robert R.} and Russell, {R. Graham G} and Whyte, {Michael P.}",
year = "2010",
month = "1",
doi = "10.1016/j.jocd.2009.12.003",
language = "English",
volume = "13",
pages = "1--9",
journal = "Journal of Clinical Densitometry",
issn = "1094-6950",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - 2009 Santa Fe Bone Symposium

AU - Lewiecki, E. Michael

AU - Bilezikian, John P.

AU - Laster, Andrew J.

AU - Miller, Paul D.

AU - Recker, Robert R.

AU - Russell, R. Graham G

AU - Whyte, Michael P.

PY - 2010/1

Y1 - 2010/1

N2 - Osteoporosis is a common skeletal disease with serious clinical consequences because of fractures. Despite the availability of clinical tools to diagnose osteoporosis and assess fracture risk, and drugs proven to reduce fracture risk, it remains a disease that is underdiagnosed and undertreated. When treatment is started, it is commonly not taken correctly or long enough to be effective. Recent advances in understanding of the regulators and mediators of bone remodeling have led to new therapeutic targets and the development of drugs that may offer advantages over current agents in reducing the burden of osteoporotic fractures. Many genetic factors that play a role in the pathogenesis of osteoporosis and metabolic bone disease have now been identified. At the 2009 Santa Fe Bone Symposium, held in Santa Fe, New Mexico, USA, the links between advances in genetics, basic bone science, recent clinical trials, and new and emerging therapeutic agents were presented and explored. Socioeconomic challenges and opportunities in the care of osteoporosis were discussed. This is a collection of medical essays based on key presentations at the 2009 Santa Fe Bone Symposium.

AB - Osteoporosis is a common skeletal disease with serious clinical consequences because of fractures. Despite the availability of clinical tools to diagnose osteoporosis and assess fracture risk, and drugs proven to reduce fracture risk, it remains a disease that is underdiagnosed and undertreated. When treatment is started, it is commonly not taken correctly or long enough to be effective. Recent advances in understanding of the regulators and mediators of bone remodeling have led to new therapeutic targets and the development of drugs that may offer advantages over current agents in reducing the burden of osteoporotic fractures. Many genetic factors that play a role in the pathogenesis of osteoporosis and metabolic bone disease have now been identified. At the 2009 Santa Fe Bone Symposium, held in Santa Fe, New Mexico, USA, the links between advances in genetics, basic bone science, recent clinical trials, and new and emerging therapeutic agents were presented and explored. Socioeconomic challenges and opportunities in the care of osteoporosis were discussed. This is a collection of medical essays based on key presentations at the 2009 Santa Fe Bone Symposium.

UR - http://www.scopus.com/inward/record.url?scp=76449093601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76449093601&partnerID=8YFLogxK

U2 - 10.1016/j.jocd.2009.12.003

DO - 10.1016/j.jocd.2009.12.003

M3 - Review article

VL - 13

SP - 1

EP - 9

JO - Journal of Clinical Densitometry

JF - Journal of Clinical Densitometry

SN - 1094-6950

IS - 1

ER -